The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.
 
Joseph A. Sparano
Stock and Other Ownership Interests - Metastat
Consulting or Advisory Role - AstraZeneca; Celgene; Celldex; Genentech/Roche; Juno Therapeutics; Lilly; Merrimack; Novartis; Pfizer; Prescient Therapeutics
Research Funding - Deciphera (Inst); Genentech/Roche (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Novartis (Inst); Prescient Therapeutics (Inst)
 
Robert James Gray
Research Funding - Abbott Molecular; Agios; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Genomic Health; Genzyme; GlaxoSmithKline; Janssen-Ortho; Millennium; Novartis; Onyx; Pfizer; Sanofi; Sequenta; Syndax
 
William C. Wood
No Relationships to Disclose
 
Della F. Makower
No Relationships to Disclose
 
Tracy G. Lively
No Relationships to Disclose
 
Thomas James Saphner
No Relationships to Disclose
 
Maccon M. Keane
No Relationships to Disclose
 
Henry Leonidas Gomez
No Relationships to Disclose
 
Pavan S. Reddy
No Relationships to Disclose
 
Timothy F Goggins
No Relationships to Disclose
 
Ingrid A. Mayer
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis
Research Funding - Novartis; Pfizer
 
Deborah Toppmeyer
Employment - Novartis (I)
Leadership - Novartis (I)
Stock and Other Ownership Interests - Novartis (I)
Consulting or Advisory Role - Merck
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Bayer; bioTheranostics; Celgene; Genentech/Roche; Genomic Health; Lilly; NanoString Technologies; Novartis; Pfizer; Puma Biotechnology
 
Matthew P. Goetz
Consulting or Advisory Role - bioTheranostics; Eisai; Genomic Health; Lilly; Novartis
Research Funding - Lilly; Pfizer
Patents, Royalties, Other Intellectual Property - Methods and Materials for Assessing Chemotherapy Responsiveness and Treating Cancer; METHODS AND MATERIALS FOR USING BUTYRYLCHOLINESTERASES TO TREAT CANCER
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion; OncImmune
Consulting or Advisory Role - Cepheid
Research Funding - AstraZeneca (Inst); Lilly (Inst); Menarini (Inst); Merrimack (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Other Relationship - Menarini
 
Elizabeth Claire Dees
Consulting or Advisory Role - Novartis (I)
Research Funding - Bayer; Cerulean Pharma; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
 
Kathleen I. Pritchard
Honoraria - Amgen; Eisai; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; Eisai; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Amgen; Eisai; Novartis; Pfizer; Roche
 
Charles E. Geyer
Consulting or Advisory Role - Celgene; HERON; Myriad Genetics
Research Funding - Merck
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech/Roche
 
John A. Olson
No Relationships to Disclose
 
George W. Sledge
Leadership - Syndax
Stock and Other Ownership Interests - Syndax
Honoraria - Symphony Evolution
Consulting or Advisory Role - Coherus Biosciences; Peregrine Pharmaceuticals; Radius Health; Symphony Evolution; Taiho Pharmaceutical
Research Funding - Genentech/Roche (Inst)
Travel, Accommodations, Expenses - Radius Health; Taiho Pharmaceutical